20-F: Materialise NV Reports Mixed Financial Performance

Materialise NV's 2025 annual report shows a slight revenue increase but a significant drop in net profit, with the Medical segment showing strong growth while Manufacturing struggles.

Summary

• Materialise NV reported a 0.3% increase in revenue for the year ended December 31, 2025, reaching €267.6 million, up from €266.8 million in 2024.
• Net profit for the year decreased by 42.5% to €7.7 million, compared to €13.4 million in the previous year.
• The Materialise Medical segment saw revenue grow by 15.4% to €134.2 million, with strong performance in medical devices and services.
• The Materialise Software segment experienced a 6.8% decrease in revenue to €40.9 million, despite an increase in recurrent revenue.
• The Materialise Manufacturing segment reported a 13.2% revenue decline to €92.5 million, attributed to unfavorable market conditions and ongoing investments.
• Adjusted EBITDA increased by 2.9% to €32.4 million, and Adjusted EBIT increased by 9.1% to €10.6 million.
• Capital expenditures decreased significantly to €16.3 million in 2025 from €26.4 million in 2024, primarily due to the completion of major facility expansions.
• The company's cash and cash equivalents increased to €133.9 million as of December 31, 2025.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as cautiously negative due to the significant drop in net profit and revenue decline in key segments, despite positive growth in the Medical segment and improved Adjusted EBITDA/EBIT. The company faces ongoing market challenges and the need for strategic adaptation.

Positives

• Revenue saw a slight increase of 0.3% to €267.6 million.
• The Materialise Medical segment demonstrated robust growth with a 15.4% revenue increase to €134.2 million.
• Adjusted EBITDA and Adjusted EBIT showed positive year-over-year growth, increasing by 2.9% and 9.1% respectively.
• The company's cash and cash equivalents position strengthened, ending the year at €133.9 million.
• The Materialise Software segment's recurrent revenue increased by 3.9%, indicating a stable base for future growth.
• The company successfully completed the listing of its ordinary shares on Euronext Brussels in November 2025.

Negatives

• Net profit experienced a significant decline of 42.5% to €7.7 million.
• The Materialise Manufacturing segment's revenue decreased by 13.2% to €92.5 million due to unfavorable market conditions.
• The Materialise Software segment's revenue decreased by 6.8% to €40.9 million, with a substantial drop in non-recurrent revenue.
• Net financial expenses increased to €1.6 million in 2025 from a net financial income of €4.7 million in 2024.
• The company incurred €0.8 million in non-recurring expenses related to the Euronext Brussels listing.

Risks

• The growth of the additive manufacturing market is uncertain, and the company may not be able to maintain or increase its market share or reputation.
• The transition to cloud-based software subscription models may not be successfully developed or implemented.
• The company is dependent on sales to the industrial and medical industries, particularly automotive/aerospace and orthopedic/cranio-maxillofacial segments, and downturns in these sectors could adversely affect results.
• Disruptions to information technology systems, including security breaches, could adversely affect operations.
• International operations expose the company to global and local economic, social, political, and operational risks, including geopolitical instability and currency fluctuations.
• Errors or defects in software or products could lead to additional costs, lost revenue, reputational damage, and potential liability.
• The company's medical business is subject to substantial government regulations and healthcare policy changes.
• The company's inability to protect its intellectual property rights could harm its business.
• The company's ordinary shares and ADSs may experience price and volume fluctuations, and future sales could adversely affect market value.
• The company has no present intention to pay cash dividends in the foreseeable future, meaning investor returns rely on share price appreciation.

Future Outlook

The company intends to continue investing in research and development, particularly in cloud-based software solutions and the expansion of certified 3D manufacturing environments for end-use products. Growth is expected to be driven by the Materialise Medical segment's focus on personalized patient care and the Materialise Software segment's transition to cloud-based models. However, the company acknowledges potential near-term revenue impacts from this transition and ongoing investments.

Management Comments

• The company's mission is to innovate product development that results in a better and healthier world, through its software and hardware infrastructure, and an in-depth knowledge of additive manufacturing.
• The company believes its focus on the choice for sustainability will position it for long-term sustainable growth, even if this may imply foregoing short-term growth opportunities that do not fit this vision.
• The company is investing significantly in the development of new product offerings and the optimization of existing offerings in terms of cost and lead times, as well as in the expansion of its distribution channel in the various sub-segments of its Materialise Medical segment and in new territories.

Industry Context

StockSavvy.ai notes that Materialise NV operates in the highly competitive and rapidly evolving additive manufacturing and medical technology sectors. The company's performance is influenced by broader industry trends such as the increasing adoption of 3D printing for end-use parts, the shift towards cloud-based software models, and the growing demand for personalized medical solutions. The company's strategy to focus on sustainability and innovation positions it to capitalize on these trends, although it also faces challenges from intense competition and the need for continuous technological advancement.

Comparison to Industry Standards

• The company's Materialise Medical segment's Adjusted EBITDA margin of 32.0% in 2025 is strong, but direct comparisons to specific industry benchmarks are not provided in the filing.
• The Materialise Software segment's Adjusted EBITDA margin of 13.4% in 2025 indicates a more challenging competitive landscape compared to the Medical segment.
• The Materialise Manufacturing segment's negative Adjusted EBITDA margin of -4.6% in 2025 highlights significant industry headwinds and the need for operational improvements or strategic shifts in this segment.

Legal Proceedings

• The Group is currently not a party to any legal or arbitration proceedings that are likely to have or could reasonably possibly have a material adverse effect on the business, financial position or results of operations.

Related Party Transactions

• Rent expense of €314 paid to Lunebeke NV in 2025 for hosting employees.

Stakeholder Impact

• Shareholders may see reduced returns due to the decline in net profit and the lack of immediate dividend payments, with returns primarily dependent on share price appreciation.
• Employees in the Materialise Manufacturing segment may face uncertainty due to unfavorable market conditions impacting revenue.
• Customers in the Materialise Manufacturing segment may experience potential impacts from the company's strategic adjustments due to market conditions.
• Suppliers may be affected by changes in production volumes, particularly in the Materialise Manufacturing segment.

Next Steps

• Continue to invest in research and development for new product offerings and optimization of existing ones.
• Expand distribution channels in various sub-segments of the Materialise Medical segment and in new territories.
• Strengthen market penetration of the software platform by growing the position of the Magics 3D Print Suite and bringing the CO-AM platform to market.
• Initiate ADS and/or share buyback program for up to €30.0 million, expected to commence by January 2026.

Key Dates

Recommendation

While the Medical segment shows strong growth and Adjusted EBITDA/EBIT improved, the significant drop in net profit and revenue decline in the Software and Manufacturing segments, coupled with ongoing market uncertainties and the company's focus on reinvestment rather than dividends, suggest a cautious approach. The company's strategic investments and market position warrant a 'hold' rating pending clearer signs of sustained profitability improvement across all segments.

Keywords

Materialise NV, 3D printing, Additive Manufacturing, Medical Devices, Software, SEC Filing, Form 20-F, Financial Report, Revenue, Net Profit, EBITDA, EBIT, Materialise Medical, Materialise Software, Materialise Manufacturing